Get started
GILEAD SCIENCES INCGILEAD SCIENCES INCGILEAD SCIENCES INC

GILEAD SCIENCES INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

GILDCL chart


Full chart

Key facts today

Gilead Sciences has secured the option to further develop and commercialize Assembly Biosciences' investigational antiviral drug ABI-4334, contingent upon the completion of the ongoing phase 1b study.
Analyze the impactAnalyze the impact

GILDCL upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪116.50 T‬ CLP
Dividend yield (indicated)
3.28%
Price to earnings Ratio (TTM)
895
Basic EPS (TTM)
90 CLP
Net income (FY)
‪4.99 T‬ CLP
Revenue (FY)
‪23.86 T‬ CLP
Shares float
‪1.24 B‬
Beta (1Y)
0.51

Employees


Employees (FY)
‪18 K‬
Change (1Y)
‪+1 K‬ +5.88%
Revenue / Employee (1Y)
‪1.33 B‬ CLP
Net income / Employee (1Y)
‪277.48 M‬ CLP

About Gilead Sciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Daniel P. O'Day
Website
gilead.com
Headquarters
Foster City
Founded
1987
FIGI
BBG00YFSDB53
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GILDCL news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

GILDCL highest yielding bonds


GILD5050849
Gilead Sciences, Inc. 2.8% 01-OCT-2050
Yield to maturity
6.88%
Maturity date
Oct 1, 2050
US375558BS1
GILEAD SCIEN 20/40
Yield to maturity
6.68%
Maturity date
Oct 1, 2040
US375558BK8
GILEAD SCIENCES 16/47
Yield to maturity
6.33%
Maturity date
Mar 1, 2047
GILD4184058
Gilead Sciences, Inc. 4.5% 01-FEB-2045
Yield to maturity
6.09%
Maturity date
Feb 1, 2045
GISE
GILEAD SCIENCES 2046
Yield to maturity
6.08%
Maturity date
Mar 1, 2046
GILD4104362
Gilead Sciences, Inc. 4.8% 01-APR-2044
Yield to maturity
5.96%
Maturity date
Apr 1, 2044
GISG
GILEAD SCIENCES 16/36
Yield to maturity
5.77%
Maturity date
Sep 1, 2036
GILD5939386
Gilead Sciences, Inc. 5.6% 15-NOV-2064
Yield to maturity
5.77%
Maturity date
Nov 15, 2064
GILD5648609
Gilead Sciences, Inc. 5.55% 15-OCT-2053
Yield to maturity
5.73%
Maturity date
Oct 15, 2053
GILD5939385
Gilead Sciences, Inc. 5.5% 15-NOV-2054
Yield to maturity
5.71%
Maturity date
Nov 15, 2054
GILD.GO
Gilead Sciences, Inc. 5.65% 01-DEC-2041
Yield to maturity
5.57%
Maturity date
Dec 1, 2041

Explore more bonds 

Sparks


Curated watchlists where GILDCL is featured.

See all sparks 

Frequently Asked Questions


The current price of GILDCL is 79,000 CLP — it hasn't changed in the past 24 hours. Watch GILEAD SCIENCES INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BCS exchange GILEAD SCIENCES INC stocks are traded under the ticker GILDCL.
We've gathered analysts' opinions on GILEAD SCIENCES INC future price: according to them, GILDCL price has a max estimate of 124,378.11 CLP and a min estimate of 72,636.82 CLP. Watch GILDCL chart and read a more detailed GILEAD SCIENCES INC stock forecast: see what analysts think of GILEAD SCIENCES INC and suggest that you do with its stocks.
GILDCL reached its all-time high on Dec 16, 2024 with the price of 92,246 CLP, and its all-time low was 47,200 CLP and was reached on Apr 16, 2021. View more price dynamics on GILDCL chart.
See other stocks reaching their highest and lowest prices.
GILDCL stock is 16.77% volatile and has beta coefficient of 0.51. Track GILEAD SCIENCES INC stock price on the chart and check out the list of the most volatile stocks — is GILEAD SCIENCES INC there?
Today GILEAD SCIENCES INC has the market capitalization of ‪116.39 T‬, it has increased by 3.20% over the last week.
Yes, you can track GILEAD SCIENCES INC financials in yearly and quarterly reports right on TradingView.
GILEAD SCIENCES INC is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
GILDCL earnings for the last quarter are ‪1.82 K‬ CLP per share, whereas the estimation was ‪1.38 K‬ CLP resulting in a 32.02% surprise. The estimated earnings for the next quarter are ‪1.70 K‬ CLP per share. See more details about GILEAD SCIENCES INC earnings.
GILEAD SCIENCES INC revenue for the last quarter amounts to ‪6.80 T‬ CLP, despite the estimated figure of ‪6.33 T‬ CLP. In the next quarter, revenue is expected to reach ‪7.11 T‬ CLP.
GILDCL net income for the last quarter is ‪1.13 T‬ CLP, while the quarter before that showed ‪1.52 T‬ CLP of net income which accounts for −25.87% change. Track more GILEAD SCIENCES INC financial stats to get the full picture.
Yes, GILDCL dividends are paid quarterly. The last dividend per share was 762.38 CLP. As of today, Dividend Yield (TTM)% is 3.26%. Tracking GILEAD SCIENCES INC dividends might help you take more informed decisions.
GILEAD SCIENCES INC dividend yield was 3.70% in 2023, and payout ratio reached 66.62%. The year before the numbers were 3.40% and 80.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 27, 2024, the company has ‪18.00 K‬ employees. See our rating of the largest employees — is GILEAD SCIENCES INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GILEAD SCIENCES INC EBITDA is ‪12.04 T‬ CLP, and current EBITDA margin is 45.96%. See more stats in GILEAD SCIENCES INC financial statements.
Like other stocks, GILDCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GILEAD SCIENCES INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GILEAD SCIENCES INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GILEAD SCIENCES INC stock shows the buy signal. See more of GILEAD SCIENCES INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.